TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00892567

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 9 Peptides from Her-2/neu, CEA, & CTA
Description: Each vaccination will be administered on days 1, 8, 15, 36, 43, and 50. All participants will receive 9 class I MHC-restricted synthetic peptides and a class II MHC-restricted tetanus helper peptide administered in Montanide ISA-51. The vaccine will be administered subcutaneously (1 ml) and intradermally (1ml) at a single vaccination site.
Study: NCT01253252

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [18F] Fluorodeoxyglucose PET Scan Imaging
Description: Positron Emission Tomography (PET) is a nuclear medicine imaging technique which produces a 3-dimensional image of functional processes in the body. The system detects pairs of gamma rays emitted indirectly by a positron-emitting radionuclide, which is introduced into the body on a biologically active molecule. Images of tracer concentration in 3-dimensional space are then reconstructed by computer analysis.~The biologically active molecule chosen for PET is 18-fluorodeoxyglucose. The concentrations of tracer imaged then give tissue metabolic activity, in terms of regional glucose uptake.~The dose of 18FDG that is recommended for adults in a standard exploration varies from 200 to 500 MBq according to the weight of the patient and the camera used. No allergic or other incident has been observed after several thousands of examinations.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: CT scan
Description: Computed tomography (CT) is a medical imaging method employing tomography created by computer processing. Digital geometry processing is used to generate the PET's three-dimensional space image.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sampling for biological investigations
Description: A venous blood sample of a total of 30 ml for measurement of enzymes associated with the development of aneurysms (= biomarkers).
Study: NCT02786485

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rivogenlecleucel
Description: T cells transduced with iCasp safety switch

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rimiducid
Description: administered to treat GVHD
Study: NCT04637958

Intervention type: DEVICE
Intervention: THA
Description: Total hip arthroplasty

Intervention type: DEVICE
Intervention: THA
Description: Total hip arthroplasty
Study: NCT02557269

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xylometazoline - intranasal application
Description: Applied as needed up to 5 consecutive days when prominent congestion

Intervention type: DRUG
Group type: OTHER
Intervention: Xylometazoline - intranasal application
Description: Applied as needed up to 5 consecutive days when prominent congestion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Xylometazoline - intranasal application
Description: Applied as needed up to 5 consecutive days when prominent congestion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azelastine - intranasal application
Description: Applied as needed when prominent symptom is rhinorrhea

Intervention type: DRUG
Group type: OTHER
Intervention: Azelastine - intranasal application
Description: Applied as needed when prominent symptom is rhinorrhea
Study: NCT01841593

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: Isentress 400mg tablet taken twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Description: generic amlodipine 5mg tablets (Accord healthcare Limited, UK)
Study: NCT02557269

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Azelastine - intranasal application
Description: Applied as needed when prominent symptom is rhinorrhea

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mometasone furoate - intranasal application
Description: Applied once daily (2 puffs) when no satisfactory therapeutic control from other intranasal treatment

Intervention type: DRUG
Group type: OTHER
Intervention: Mometasone furoate - intranasal application
Description: Applied once daily (2 puffs) when no satisfactory therapeutic control from other intranasal treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mometasone furoate - intranasal application
Description: Applied once daily (2 puffs) when no satisfactory therapeutic control from other intranasal treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxyl-propyl-methyl cellulose powder - intranasal application
Description: Applied intranasally immediately after every application other intranasal formulation

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Lactose powder
Description: Applied intranasally immediately after every application other intranasal formulation
Study: NCT02291861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SD-809
Description: SD-809 tablets dose titrated for 4 weeks until target randomized dose is reached. The dose is maintained for an additional 8 weeks. Tablets were swallowed whole with water and taken with food.
Study: NCT02557269

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bilastine 20 mg
Description: 1 tablet per os - as needed

Intervention type: DRUG
Group type: OTHER
Intervention: Bilastine 20 mg
Description: 1 tablet per os - as needed

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bilastine 20 mg
Description: 1 tablet per os - as needed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone 5 mg
Description: Per os - if needed (only in case of broncial obstruction)

Intervention type: DRUG
Group type: OTHER
Intervention: Prednisolone 5 mg
Description: Per os - if needed (only in case of broncial obstruction)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisolone 5 mg
Description: Per os - if needed (only in case of broncial obstruction)
Study: NCT02291861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SD-809
Description: SD-809 tablets dose titrated for 4 weeks until target randomized dose is reached. The dose is maintained for an additional 8 weeks. Tablets were swallowed whole with water and taken with food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SD-809
Description: SD-809 tablets dose titrated for 4 weeks until target randomized dose is reached. The dose is maintained for an additional 8 weeks. Tablets were swallowed whole with water and taken with food.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets taken twice daily for 12 weeks. Tablets were swallowed whole with water and taken with food.
Study: NCT03663049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: discontinue statin
Description: Discontinue statin as prescribed for 12 weeks
Study: NCT04400773

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plyometric exercises
Description: Types of exercises include resistance tubing 90-90 external rotation, plyometric push-up, reverse overhead throws, rotational wall throw, overhead medicine ball, chest passes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength training exercises
Description: Types of exercise include push-ups, resisted external rotation, overhead presses, biceps curl, bench presses and triceps kick backs.
Study: NCT00223990

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FMP1/AS02A
Description: FMP1/AS02A candidate malaria vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RabAvert
Description: RabAvert rabies vaccine
Study: NCT00267202

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Doses of placebo were administered subcutaneously every 2 to 4 weeks according to the US product label, depending on the patient's body weight and baseline serum IgE.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omalizumab
Description: Doses of omalizumab were administered subcutaneously every 2 to 4 weeks according to the US product label, depending on the patient's body weight and baseline serum IgE.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Immunotherapy
Description: Customized allergen extracts were prepared centrally for each patient based on his/her specific skin test results. Four vials containing dilutions of the patient's extract were provided. Investigators initiated dosing according to the protocol for the cluster dosing titration regimen, beginning with vial #4 (the most dilute) and progressing to vial #1, which was the most concentrated or maintenance solution. Each dose was administered subcutaneously into the deltoid region as a single injection. During study visits that required multiple IT injections, each injection was to be given at least 30 minutes apart. During weeks that required multiple visits for IT injections, each visit was to be separated by at least 48 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunotherapy
Description: Customized allergen extracts were prepared centrally for each patient based on his/her specific skin test results. Four vials containing dilutions of the patient's extract were provided. Investigators initiated dosing according to the protocol for the cluster dosing titration regimen, beginning with vial #4 (the most dilute) and progressing to vial #1, which was the most concentrated or maintenance solution. Each dose was administered subcutaneously into the deltoid region as a single injection. During study visits that required multiple IT injections, each injection was to be given at least 30 minutes apart. During weeks that required multiple visits for IT injections, each visit was to be separated by at least 48 hours.
Study: NCT05728710

Intervention type: PROCEDURE
Intervention: Endoscopic submucosal dissection
Description: standard ESD performed and complicated with a perprocedural or delayed perforation
Study: NCT01766466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cangrelor
Description: Open-label cangrelor IV bolus (30 µg/kg), followed by an infusion of 4 µg/kg/min for two hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cangrelor
Description: Open-label cangrelor IV bolus (30 µg/kg), followed by an infusion of 4 µg/kg/min for two hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cangrelor
Description: Open-label cangrelor IV bolus (30 µg/kg), followed by an infusion of 4 µg/kg/min for two hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cangrelor
Description: Open-label cangrelor IV bolus (30 µg/kg), followed by an infusion of 4 µg/kg/min for two hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Ticagrelor 180mg dose: administered 0.5 h or 1.5h after the initiation of cangrelor infusion~Ticagrelor 90mg: 6 or 7 doses (depending on study arm) taken every 12 hours post cangrelor infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Ticagrelor 180mg dose: administered 0.5 h or 1.5h after the initiation of cangrelor infusion~Ticagrelor 90mg: 6 or 7 doses (depending on study arm) taken every 12 hours post cangrelor infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Ticagrelor 180mg dose: administered 0.5 h or 1.5h after the initiation of cangrelor infusion~Ticagrelor 90mg: 6 or 7 doses (depending on study arm) taken every 12 hours post cangrelor infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Ticagrelor 180mg dose: administered 0.5 h or 1.5h after the initiation of cangrelor infusion~Ticagrelor 90mg: 6 or 7 doses (depending on study arm) taken every 12 hours post cangrelor infusion.
Study: NCT00830310

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducation module
Description: Individuals will be assigned the psychoeducation module if they are identified as having opposition to prophylaxis, denial of illness severity or therapeutic effectiveness, negative attitudes towards drugs in general, or lack of information about mood stabilizers operationalized as a score of 1 or higher on any of these AMSQ subscales. Additionally, those individuals who are non-adherent/sub-optimally adherent because of stigma or embarrassment over medications or in relation to the use of complementary or alternative treatments will be assigned to participate in the psychoeducation module (ROMI stigma item or complementary/alternative treatment supplemental item).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Substance use module
Description: Individuals will be assigned the substance use module if they endorse the ROMI substance use item or if substance use is identified as problematic on the clinician assessment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Improved communication/rapport with provider module
Description: Individuals will be assigned the provider communication/rapport module if they are identified as having fear of side effects operationalized as a score of 1 or higher on these AMSQ items. Additionally, those individuals who are non-adherent/suboptimally adherent because of concern regarding change in appearance appearing medicated or who experience side-effect-related distress as identified by the ROMI will be assigned the provider communication module.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medication routines management module
Description: Individuals will be assigned the medication routines management module if they are identified as having difficulties with medication routines operationalized as a score of 1 or higher on this AMSQ sub-scale, or if they are identified as experiencing outside opposition to medications by the ROMI.
Study: NCT03836040

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erenumab Dose 1
Description: Participants in the low body-weight group at day 1 and who are randomized to Dose Level 1 will receive this dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erenumab Dose 2
Description: Participants in the low body-weight group at day 1 who are randomized to Dose Level 2 and subjects in the high body-weight group at day 1 who are randomized to Dose Level 1 will receive this dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erenumab Dose 2
Description: Participants in the low body-weight group at day 1 who are randomized to Dose Level 2 and subjects in the high body-weight group at day 1 who are randomized to Dose Level 1 will receive this dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erenumab Dose 3
Description: Participants in the high body-weight group at day 1 who are randomized to Dose Level 2 will receive this dose.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching dose for erenumab dose 1, 2 and 3.
Study: NCT02254876

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard physical therapy program
Description: Standard physical therapy program in this study involves joint health and passive mobility at the level of the shoulder girdle and upper limb affected by Painful Shoulder Syndrome associated with the modulation of hypertonic muscle groups.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard physical therapy program
Description: Standard physical therapy program in this study involves joint health and passive mobility at the level of the shoulder girdle and upper limb affected by Painful Shoulder Syndrome associated with the modulation of hypertonic muscle groups.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NeuroMuscular Taping (NMT)
Description: The NeuroMuscular Taping (NMT) consists of the application on the skin of an adhesive tape with a particular structure to elastic waves and with characteristics comparable to those cutaneous. Because of these characterises it allows activation of endogenous analgesic, structural and muscular support, vascular and lymphatic activation.~In this study the NMT is applied with decompressive mode on Pectoralis Major, Deltoids, Supraspinatus.
Study: NCT04029246

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Follow up phone call
Description: Telephone call to ask if patient has received letter and whether they would like an appointment

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Incentive
Description: Offer of a shopping voucher if patient attends for appointment
Study: NCT00370994

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Caudal epidural injection
Description: Caudal epidural injection with catheterization

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous adhesiolysis
Description: Percutaneous adhesiolysis with hypertonic saline neurolysis
Study: NCT02298790

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meal schedule

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meal schedule
Study: NCT00514059

Intervention type: DRUG
Group type: OTHER
Intervention: Boostrix polio
Description: 1 dose (0.5 ml) i.m.
Study: NCT02699918

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: nocturnal oximetry
Description: nocturnal oximetry for screening of sleep apnea syndrome. Patients with abnormal nocturnal oximetry will be further explored by polysomnography.
Study: NCT01841593

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Description: generic amlodipine 5mg tablets (Accord healthcare Limited, UK)
Study: NCT01288716

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arbaclofen
Study: NCT02086110

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Synbiotic

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Synbiotic

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Prebiotic

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Prebiotic
Study: NCT03576248

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: In-phase 6 Hz prefronto-parietal tACS
Description: tACS is a non-invasive stimulation technique that works by delivering a weak sinusoidally oscillating electrical current to the surface of the skull to entrain oscillations in the brain.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham prefronto-parietal tACS
Description: tACS is a non-invasive stimulation technique that works by delivering a weak sinusoidally oscillating electrical current to the surface of the skull to entrain oscillations in the brain.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 2 mA left prefrontal tDCS
Description: tDCS is a form of neuromodulation method where very low levels of constant current are delivered to specifically targeted areas of the brain
Study: NCT04610125

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Auto CAR-T
Description: Biological: Auto CAR-T
Study: NCT03576248

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham left prefrontal tDCS
Description: tDCS is a form of neuromodulation method where very low levels of constant current are delivered to specifically targeted areas of the brain
Study: NCT02983071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G1T38

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G1T38

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Study: NCT05087654

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combination of 3D VR and Hands-on Horticultural Activities
Description: The intervention program consisted of 8 two-hour sessions that were conducted once a week for 8 consecutive weeks.
Study: NCT01351116

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: EBR
Description: EBR of 20 Gy in 5 daily fractions over one week
Study: NCT01627938

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexrazoxane (DRZ) plus Mitoxantrone (MX)
Description: Dosage: DRZ (600 mg/m2) : MX (12 mg/m2) ratio 50:1 DRZ infusion / MX infusion once every three months over a period of 12 months, i.e. 5 infusions

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo plus Mitoxantrone (MX)
Description: MX Dosage: 12mg/m2 Placebo infusion / MX infusion once every three months over a period of 12 months, i.e. 5 infusions
Study: NCT01649258

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: granisetron transdermal system
Description: Given granisetron transdermal system patch

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fosaprepitant dimeglumine
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT00096512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02619695

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fastjel
Description: 2.5% ketoprofen gel (Fastjel) has been administer as 2 gr in 5 cm area.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fastjel
Description: 2.5% ketoprofen gel (Fastjel) has been administer as 2 gr in 5 cm area.
Study: NCT01869192

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin
Description: Epirubicin 90 mg/m2 d1 q3w

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Cyclophosphamide 600 mg/m2 d1 q3w

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel 75 mg/m2 d1 q3w

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine 1000 mg/m2/dose bid x 14d q3w

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy
Description: Standard dosing, fields depending on clinical findings

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy
Description: Standard dosing, fields depending on clinical findings
Study: NCT00640705

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: diclofenac sodium
Description: 15 mg (1%) topical patch; measuring 7 cm by 10 cm; applied once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo patch
Description: Matching placebo patch, containing identical constituents to the active comparator except for diclofenac sodium; measuring 7 cm by 10 cm; applied once daily